Novavax, Inc.
NVAX · Nasdaq · USD · Market cap $1.3B · 749 employees
Novavax, Inc., a biotechnology company, engages in the discovery, development, and commercialization of vaccines to prevent serious infectious diseases in the United States, Europe, and internationally.
FAIL · Does not pass the screenPrice as of 20 Nov 2026Daily close, not a live quote
Screened 2026-11-20 · the tape above runs as of 14:15 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed
Key facts today
- Price7.47 USD at the 20 Nov 2026 close
- Fair valueUnder review: our model's value is 2.07x the price, above our 2.00x limit.
- Our regime readDistribution, as of 15 Nov 2026
- Ethical screenDoes not pass
- OptionsOpen interest leans to puts (put/call 1.07)
- Last reviewed20 Nov 2026 (1 day ago)
- Release timesRelease and earnings times on your chart: Event Guard Mentor
A summary of the dated readings below, not a live quote and not advice.
Our fair-value range: range not available (screen dated 2026-11-20).
- Trend Distribution
- Insiders no filings inside 60 days, left as found
- Positioning no disclosures inside 60 days, left as found
- Options put/call open interest 1.07, read 2026-11-18
- Ethical does not pass the values gate
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
This name holds its distribution label.
Novavax, Inc. holds its Distribution at $7.47. The statistical read favours the sellers, held for 13 days.
| Phase | Distribution · caution |
| Quantitative state | The statistical read favours the sellers, held for 13 days |
| Price at the screen | $7.47 |
| Valuation | N/A trailing · -44.22 forward price to earnings |
| Values screen | FAIL · score 70.0 |
| Beta | 2.72 |
Five Screens: NVAX's Results
FAIL. Interest-bearing securities
| Test | Figure | Limit | Status |
|---|---|---|---|
| Business activity | Permissible | Permissible core business | Pass |
| Debt load | 21.15% | Below 33% | Pass |
| Interest-bearing cash | 42.03% | Below 33% | Fail |
| Receivables | 29.50% | Below 49% | Pass |
| Revenue purity | 2.63% | Below 5% | Pass |
Definitions, sources and threshold rules: ticker values-screen methodology.
The Ethical ReadWhy It Falls Short, in Plain English
Novavax,'s business is fine, but its cash and interest-bearing securities are about 42% of its assets, well over the ~33% line, so it does not pass on the financial screens.
Read as at 20 Nov 2026. It updates when the underlying figures move, and past reads are kept below. How we screen.
Follow this verdict
Get an email when NVAX's ethical verdict changes
Today NVAX does not pass the screen. If new figures move it to a pass, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.
Free, no account needed. Every email has a link to stop.
The Fair Value Range
Fair value under review. Our model's value is 2.07x the price, above our 2.00x limit. We show no fair value, margin of safety or value read built on it until the review clears.
The Street's RangeStreet: 9 covering, consensus Buy. Average target +114%.
| Forward P/E | -44.2x |
| EPS, trailing | -0.52 |
| EPS, forward | -0.18 |
| Revenue growth | -3.0%revenue is shrinking |
| Profit margin | -18.6%currently unprofitable |
| FCF yield | 0.90% |
| Current ratio | 2.15comfortably covers its short-term bills |
| Beta | 2.72much more volatile than the market |
| Short interest, float | 0.28% |
| 52-week range | 6.20 - 13.39 |
| Market cap | $1.3B |
| Employees | 749 |
NVAX-specific watchpoints · The things to watch: it's a small-cap, so the share price can swing harder than the market; it already moves more than the market on an average day; as a biotechnology name, trial and regulatory outcomes can move it sharply either way.
Metric definitions and interpretation rules: ticker-page methodology.
Every Entry, As Written
Since the last review it saw its composite score ease.
The framework has shifted from markup to distribution since the last review.
The framework has shifted from distribution to markup since the last review.
Earnings landed in this window. Ethical screening: FAIL.
Written on its date, before the outcome; never pruned.
- Novavax to Participate in Jefferies London Healthcare Conference Yahoo Finance · 10d ago
- NVAX Q3 2026 deep dive: Sanofi milestone and cost controls shape outlook Yahoo Finance · 11d ago
- Novavax, Inc. (NVAX) Is a Trending Stock: Facts to Know Before Betting on It Yahoo Finance · 11d ago
- Novavax (NVAX) stock trades up, here is why Yahoo Finance · 11d ago
- Novavax (NVAX) Looks Cheap After Sanofi Milestone And Stronger Q3 Results Yahoo Finance · 14d ago
Headlines from third-party outlets, linked for reference: not our reporting, not advice.
Screened names in the same industry · explore each on its own page.
| Period | Price then | Price return | Divs per share | $1,000 became | Total return |
|---|---|---|---|---|---|
| 1 month | $9.50 | -10.3% | · | $897 | -10.3% |
| 2 months | $8.12 | +4.9% | · | $1,049 | +4.9% |
| 3 months | $10.30 | -17.3% | · | $827 | -17.3% |
| 6 months | $6.69 | +27.4% | · | $1,274 | +27.4% |
| 1 year | $7.20 | +18.3% | · | $1,183 | +18.3% |
| 2 years | $16.01 | -46.8% | · | $532 | -46.8% |
| 3 years | $7.47 | +14.1% | · | $1,141 | +14.1% |
| 5 years | $209.68 | -95.9% | · | $41 | -95.9% |
Historical returns from market close data. Past performance does not guarantee future results.
This entry now belongs to the ledger. Whatever NVAX does next, these words stay.
Thirteen thousand names carry this page. One desk keeps them honest.
Membership opens the full screen archive, the composites built from it, and the daily coverage that prices what the screen approves.
Join the deskScreening is research, not a fatwa and not financial advice. Figures are drawn from public accounts at the screen date shown. Always manage your risk.